- Home
- SSM vs RNAZ Comparison
SSM vs RNAZ Comparison
Compare SSM & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SSM | RNAZ |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | Germany | United States |
| Employees | 23 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 5.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SSM | RNAZ |
|---|---|---|
| Price | $3.90 | $8.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.8K | ★ 24.6K |
| Earning Date | 05-20-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,462,987.20 | N/A |
| Revenue Next Year | $48.49 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.42 | $3.82 |
| 52 Week High | $10.54 | $20.99 |
Technical Indicators
Market Signals| Indicator | SSM | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 42.51 | 64.77 |
| Support Level | $3.61 | $8.38 |
| Resistance Level | $4.49 | $9.68 |
| Average True Range (ATR) | 0.49 | 1.17 |
| MACD | 0.01 | 0.45 |
| Stochastic Oscillator | 20.00 | 74.02 |
Price Performance
Historical ComparisonAbout SSM Sono Group N.V. Ordinary Shares
Sono Group NV is engaged in the field of solar-powered electric mobility. With its proprietary solar technology, the company is able to integrate solar panels into a vehicle's bodywork, using energy captured from the sun to charge the vehicle's battery. The group is engaged in the design and development of its own first solar electric vehicle, the Sion. Its Products and services include Complete Solar Solutions, Solar Charge Controllers, Solar Modules, Data Services, and Engineering Services. The company's single business segment manages the financing, research and development, and product commercialization.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.